The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines

Blood

Volumn 90, Issue 11, 1997, Pages 4307-4312

  König, Andrea ^a   Schwartz, Gary K ^b   Mohammad, Ramzi M ^b   Al Katib, Ayad ^b   Gabrilove, Janice L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FLAVONOID; FLAVOPIRIDOL; GENISTEIN; QUERCETIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LABELING; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC LEUKEMIA; DNA STRAND; DOWN REGULATION; ENZYME INHIBITION; GROWTH DISORDER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0040932434     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4307.4307_4307_4312     Document Type: Article

References (35)

1. Suolinna EM, Lang DR, Racker E: Quercetin, an artificial regulator of the high aerobic glycolysis of tumor cells. J Natl Cancer Inst 53:1515, 1974
2. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736, 1992
3. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland P: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589, 1994
4. Bible KC, Kaufmann SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856, 1996
5. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973, 1996
6. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93:2735, 1996
7. Schwartz GK, Farsi K, Danso D, Dhupar SK, Kelsen D, Spriggs D: The protein kinase C inhibitors UCN-0l and flavopiridol enhance the effect of chemotherapy by promoting apoptosis in gastric and breast cancer cells. Proc Am Soc Clin Oncol 15:501, 1996 (abstr)
8. Senderowicz AM, Headlee D, Stinson S, Lush RM, Figg WD, Pluda J, Sausville EA: A phase I trial of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. Proc Am Soc Clin Oncol 16:226a, 1997 (abstr)
9. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL: B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL. [Review]. Blood 78:1901, 1991
10. Cheson B, Bennet J, Rai K, Grever M, Kay N, Schiffer C, Oken M, Keating M, Boldt, B, Kempin S, Foon K: Guidelines for the classification of chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152, 1988
11. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456, 1996
12. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y: Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med 171:559, 1990
13. Labalette M, Queyrel V, Masy E, Noel C, Pruvot FR, Dessaint JP: Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Transplantation 59:1714, 1995
14. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV: Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 85:439, 1993
15. Melo JV, Foroni L, Brito-Babapulle V, Luzzatto L, Catovsky D: The establishment of cell lines from chronic B cell leukaemias: Evidence of leukaemic origin by karyotypic abnormalities and lg gene rearrangement. Clin Exp Immunol 73:23, 1988
16. Wendel-Hansen V, Sallstrom J, De Campos-Lima PO, Kjellstrom G, Sandlund A, Siegbahn A, Carlsson M, Nilsson K, Rosen A: Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines. Leukemia 8:476, 1994
17. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, Abubakr YA, Dugan MC, Al-Katib A: Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model. Leukemia 10:130, 1996
18. König A, Menzel T, Lynen S, Wrazel L, Al-Katib A, Rosen A, Raveche E, Gabrilove JL: Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258, 1997
19. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53:3186, 1993
20. Petersen AJ, Brown RD, Gibson J, Pope B, Luo X-F, Schutz L, Wiley JS, Joshua DE: Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur J Haematol 56:213, 1996
21. Carlson BA, Pearlstein RA, Naik RG, Sedlacek H-H, Sausville EA, Worland PJ: Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogs. Proc Am Assoc Cancer Res 37:424, 1996 (abstr)
22. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
23. 2-M. Cancer Res 53:1328, 1993
24. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, Aoike A: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260:10, 1990
25. Liu Y, Bhalla K, Hill C, Priest DG: Evidence for involvement of tyrosine phosphorilation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 48:1265, 1994
26. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tanaka N, Okuyama A: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8:2425, 1993
27. de Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim S-H: Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518, 1997
28. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, Inagaki M, Delcros J-G, Moulinoux J-P: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclindependent kinases cdc2, cdk2, and cdk5. Eur J Biochem 243:527, 1997
29. Schwartz GK, Farsi K, Makhija S, König A, Gabrilove JL, Spriggs D: Sensitivity of tumor cells to the cyclin dependent kinase inhibitor flavopiridol (flavo) correlates with loss of bcl-2 expression. Proc Am Assoc Cancer Res 38:472, 1997 (abstr)
30. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang L-Y, Gregoire V, Estey E, Keating MJ; Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2, 1993
31. Catapano CV, Perrino FW, Fernandes DJ: Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate. J Biol Chem 268:7179, 1993
32. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176:1319, 1992
33. Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K: Autocrine and paracrine growth loops in chronic lymphocytic leukemia. [Review]. Semin Hematol 30:306, 1993
34. Keating MJ, O'Brian S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E: Nucleoside analogs in the treatment of chronic lymphocytic leukemia. [Review]. Leuk Lymphoma 10:139, 1993
35. Johnson SA: Purine analogues in the management of lymphoproliferative dioseases. [Review]. Clin Oncol (R Coll Radiol) 8:289, 1996